# Efficacy and Safety of Intravenous Neridronic Acid in CRPS-I

> **NCT02402530** · PHASE2,PHASE3 · COMPLETED · sponsor: **Grünenthal GmbH** · enrollment: 459 (actual)

## Conditions studied

- Complex Regional Pain Syndrome, Type I

## Interventions

- **DRUG:** Placebo
- **DRUG:** Neridronic acid 62.5 mg

## Key facts

- **NCT ID:** NCT02402530
- **Lead sponsor:** Grünenthal GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2016-08
- **Final completion:** 2016-11
- **Target enrollment:** 459 (ACTUAL)
- **Last updated:** 2018-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02402530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02402530, "Efficacy and Safety of Intravenous Neridronic Acid in CRPS-I". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02402530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*